A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

NCT05551117 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

192

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

Castration-Resistant Prostatic Cancer
Androgen-Independent Prostatic Cancer
Androgen-Insensitive Prostatic Cancer
Androgen-Resistant Prostatic Cancer
Hormone Refractory Prostatic Cancer
Anal Cancer
Anal Neoplasm
Carcinoma, Squamous Cell of Head and Neck
Head and Neck Squamous Cell Carcinoma
Laryngeal Squamous Cell Carcinoma
Oral Squamous Cell Carcinoma
Malignant Melanoma
Melanoma
Non-small Cell Lung Cancer
Non-small Cell Carcinoma
Small-cell Lung Cancer
Small Cell Carcinoma

Interventions

BIOLOGICAL: vobramitamab duocarmazine 2.0 mg (Arm A)
BIOLOGICAL: vobramitamab duocarmazine 2.7 mg (Arm B)
BIOLOGICAL: vobramitamab duocarmazine
DRUG: Abiraterone
DRUG: Enzalutamide

Sponsor

MacroGenics